Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.28 USD | -0.10% | +5.03% | -29.40% |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.03% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | -0.10% | ||
1 week | +5.03% | ||
Current month | +1.28% | ||
1 month | -7.05% | ||
3 months | -24.01% | ||
6 months | -34.20% | ||
Current year | -29.40% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 69 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 10.28 | -0.10% | 5,761 |
24-06-05 | 10.29 | -0.07% | 3,095 |
24-06-04 | 10.3 | +0.96% | 5,138 |
24-06-03 | 10.2 | +0.49% | 4,343 |
24-05-31 | 10.15 | +3.70% | 4,555 |
Delayed Quote Nasdaq, June 06, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-29.40% | 13.57M | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+3.26% | 22.82B | |
-10.44% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- PIRS Stock